-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the changes in China's pharmaceutical market environment, the structure adjustment and executive changes of multinational pharmaceutical companies have become more frequent
.
According to incomplete statistics, since 2022, at least six senior executives of multinational pharmaceutical companies have resigned, involving a large number of giant companies such as AstraZeneca, Novartis, and Bayer
.
On March 2, Novartis Oncology (China) announced that Xia Shaofei, head of the blood business unit, will leave Novartis in order to seek external career opportunities.
At the same time, Wang Wei, the current head of the North First District of the blood business unit, will temporarily act as his position to manage the blood business.
All the work of the marketing team and the promotion team
.
On February 28, Fresenius Kabi China announced to employees that Yang Kai, the company's vice president and chief financial officer, decided to leave the company on March 31, 2022 to seek external career development opportunities
.
On February 24, Abbott's internal news said that the organizational structure of the core diagnostics business unit was adjusted, and Tony Chan, Abbott's global vice president and president of China's core diagnostics, decided to seek external opportunities
.
At the same time, Fanny Chen was appointed as President of Abbott China Core Diagnostics, reporting to Greg Ahlberg, Senior Vice President of Commercial Operations for the Global Core Laboratory Diagnostics Business
.
On February 11, He Shuzhen, the head of AstraZeneca's China and county markets, also reported the news of his resignation
.
This is also AstraZeneca's departure from another and county market leader in China after Du Haochen's departure
.
Also in February, orthopedic giant Smith & Nephew released its 2021 financial report, announcing that its global CEO Roland Diggelmann will resign on March 31, 2022, while Deepak Nath, former president of Siemens clinical diagnostics business, will leave on April 1, 2022.
as chief executive officer
.
Separately, Robert LaCaze, head of Bayer's pharmaceutical division's oncology business, said in a statement that Bayer is "seeking the fastest possible regulatory timeline" to bring Bayer's new prostate cancer drug Nubeqa to patients with metastatic hormone-sensitive prostate cancer
.
Robert LaCaze won't be the one to complete the process, though, and he's leaving Bayer to hand over the baton to former GSK executive Christine Roth, who was previously senior vice president of GSK's global oncology business , will join Bayer on March 1 this year
.
While a large number of executives have left, there are also news of new executives from some companies
.
For example, AstraZeneca China recently announced that from March 1, 2022, Wang Jun will be appointed as AstraZeneca China Assistant Vice President and Head of the Hematology Oncology Business Unit of the Oncology Division, responsible for the marketing and sales of the Hematology Oncology line , directly reporting to Chen Kangwei, General Manager of AstraZeneca China Oncology Business Unit; recently, Takeda China announced the appointment of Yan Wei as the head of the Oncology Business Unit.
It is reported that Huang Haoyu, the former head of the Oncology Business Unit, has left at the end of 2021
.
In addition to the changes in executives, many multinational pharmaceutical companies have also reported layoffs this year, including Sanofi, Pfizer, Novartis, Biogen, Dongpei Pharmaceuticals and other multinational pharmaceutical companies have made layoff decisions.
Nofi plans to lay off about 6,000 jobs, Novartis India will cut about 400 jobs, and Pfizer will also lay off hundreds of jobs
.
From the perspective of the industry, the frequent resignations and layoffs of multinational pharmaceutical companies indicate that they are going through a new round of transition pains
.
In fact, not only multinational pharmaceutical companies, but also local pharmaceutical companies are also making adjustments, including a large number of companies such as China Resources Pharmaceutical, Dong’e Ejiao, and Harbin Pharmaceutical Co.
, Ltd.
, and many positions are involved, such as chairman, deputy general manager, and vice president
.
Overall, the entire pharmaceutical market is undergoing major changes
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to incomplete statistics, since 2022, at least six senior executives of multinational pharmaceutical companies have resigned, involving a large number of giant companies such as AstraZeneca, Novartis, and Bayer
.
On March 2, Novartis Oncology (China) announced that Xia Shaofei, head of the blood business unit, will leave Novartis in order to seek external career opportunities.
At the same time, Wang Wei, the current head of the North First District of the blood business unit, will temporarily act as his position to manage the blood business.
All the work of the marketing team and the promotion team
.
On February 28, Fresenius Kabi China announced to employees that Yang Kai, the company's vice president and chief financial officer, decided to leave the company on March 31, 2022 to seek external career development opportunities
.
On February 24, Abbott's internal news said that the organizational structure of the core diagnostics business unit was adjusted, and Tony Chan, Abbott's global vice president and president of China's core diagnostics, decided to seek external opportunities
.
At the same time, Fanny Chen was appointed as President of Abbott China Core Diagnostics, reporting to Greg Ahlberg, Senior Vice President of Commercial Operations for the Global Core Laboratory Diagnostics Business
.
On February 11, He Shuzhen, the head of AstraZeneca's China and county markets, also reported the news of his resignation
.
This is also AstraZeneca's departure from another and county market leader in China after Du Haochen's departure
.
Also in February, orthopedic giant Smith & Nephew released its 2021 financial report, announcing that its global CEO Roland Diggelmann will resign on March 31, 2022, while Deepak Nath, former president of Siemens clinical diagnostics business, will leave on April 1, 2022.
as chief executive officer
.
Separately, Robert LaCaze, head of Bayer's pharmaceutical division's oncology business, said in a statement that Bayer is "seeking the fastest possible regulatory timeline" to bring Bayer's new prostate cancer drug Nubeqa to patients with metastatic hormone-sensitive prostate cancer
.
Robert LaCaze won't be the one to complete the process, though, and he's leaving Bayer to hand over the baton to former GSK executive Christine Roth, who was previously senior vice president of GSK's global oncology business , will join Bayer on March 1 this year
.
While a large number of executives have left, there are also news of new executives from some companies
.
For example, AstraZeneca China recently announced that from March 1, 2022, Wang Jun will be appointed as AstraZeneca China Assistant Vice President and Head of the Hematology Oncology Business Unit of the Oncology Division, responsible for the marketing and sales of the Hematology Oncology line , directly reporting to Chen Kangwei, General Manager of AstraZeneca China Oncology Business Unit; recently, Takeda China announced the appointment of Yan Wei as the head of the Oncology Business Unit.
It is reported that Huang Haoyu, the former head of the Oncology Business Unit, has left at the end of 2021
.
In addition to the changes in executives, many multinational pharmaceutical companies have also reported layoffs this year, including Sanofi, Pfizer, Novartis, Biogen, Dongpei Pharmaceuticals and other multinational pharmaceutical companies have made layoff decisions.
Nofi plans to lay off about 6,000 jobs, Novartis India will cut about 400 jobs, and Pfizer will also lay off hundreds of jobs
.
From the perspective of the industry, the frequent resignations and layoffs of multinational pharmaceutical companies indicate that they are going through a new round of transition pains
.
In fact, not only multinational pharmaceutical companies, but also local pharmaceutical companies are also making adjustments, including a large number of companies such as China Resources Pharmaceutical, Dong’e Ejiao, and Harbin Pharmaceutical Co.
, Ltd.
, and many positions are involved, such as chairman, deputy general manager, and vice president
.
Overall, the entire pharmaceutical market is undergoing major changes
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
